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Protocol
AbstrACt
Introduction Treatments aiming at reperfusion of the 
acutely ischaemic brain tissue may result futile or even 
detrimental because of the so-called reperfusion injury. 
The processes contributing to reperfusion injury involve a 
number of factors, ranging from blood–brain barrier (BBB) 
disruption to circulating biomarkers. Our aim is to evaluate 
the relative effect of imaging and circulating biomarkers in 
relation to reperfusion injury.
Methods and analysis Observational hospital-based 
study that will include 140 patients who had ischaemic 
stroke, treated with systemic thrombolysis, endovascular 
treatment or both. BBB disruption will be assessed with 
CT perfusion (CTP) before treatment, and levels of a large 
panel of biomarkers will be measured before intervention 
and after 24 hours. Relevant outcomes will include: (1) 
reperfusion injury, defined as radiologically relevant 
haemorrhagic transformation at 24 hours and (2) clinical 
status 3 months after the index stroke. We will investigate 
the separate and combined effect of pretreatment BBB 
disruption and circulating biomarkers on reperfusion injury 
and clinical status at 3 months. Study protocol is registered 
at http://www. clinicaltrials. gov ( ClinicalTrials. gov ID: 
NCT03041753).
Ethics and dissemination The study protocol has been 
approved by ethics committee of the Azienda Ospedaliero 
Universitaria Careggi (Università degli Studi di Firenze). 
Informed consent is obtained by each patient at time of 
enrolment or deferred when the participant lacks the 
capacity to provide consent during the acute phase. 
Researchers interested in testing hypotheses with the 
data are encouraged to contact the corresponding author. 
Results from the study will be disseminated at national 
and international conferences and in medical thesis.
trial registration number NCT03041753.
IntroduCtIon 
Ischaemic stroke is a major cause of death and 
disability. The target of treatments aiming at 
recanalisation of the occluded vessel is the 
reperfusion of the ischaemic brain tissue. 
However, reperfusion of the acutely isch-
aemic tissue may result clinically futile, or 
even detrimental because of the so-called 
reperfusion injury.1 Reperfusion injury is 
a pathophysiological term that describes 
complex biochemical mechanisms that may 
boost the damage of the ischaemic tissue, 
even with successful recanalisation of the 
occluded vessel.2 Haemorrhagic transforma-
tion (HT) may be considered as expression of 
the reperfusion injury. Preliminary evidence 
showed that the disruption of the blood–brain 
barrier (BBB), which can be investigated by 
strengths and limitations of this study
 ► Using a definite protocol, a prospective collection of 
data, and an adequate number of patients assuring 
statistically powered data, Reperfusion Injury after 
ischemic Stroke Study (RISKS) can integrate sub-
stantially scanty clinical information about biological 
factors involved in reperfusion injury after cerebral 
ischaemia.
 ► RISKS combines advanced neuroimaging tech-
niques for the study of blood–brain barrier dis-
ruption with analyses of circulating biomarkers as 
potential predictors of reperfusion injury after acute 
phase interventions.
 ► A limitation of the study is the lack of a control group 
of patients who had a stroke not treated with revas-
cularisation therapies.
 ► Another limitation is that study will include patients 
with acute ischaemic stroke treated with intrave-
nous thrombolysis, endovascular treatment or both. 
This heterogeneity might influence levels of circulat-
ing biomarkers at 24 hours.
 ► A further limitation is the lack of standardisation for 
the assessment of recanalisation.
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MR techniques3 or CT using permeability maps,4 is a key 
phenomenon of the reperfusion injury.1 2 Experimental 
studies on cerebral ischaemia have demonstrated that 
a number of biological factors, including inflammatory 
mediators, matrix metalloproteinases (MMPs) and endo-
thelial function mediators may contribute to reperfusion 
injury.5 Specifically, unbalance of MMP levels and their 
natural inhibitors (tissue  inhibitor of metalloprotein-
ases) seem to be associated with disruption of BBB and 
increased risk of HT.6–8 However, scanty clinical data exist 
about relationships between circulating and imaging 
biomarkers of reperfusion injury.9 10 In this single-centre, 
prospective observational study of patients who had an 
ischaemic stroke treated with recanalisation therapies, 
we plan to investigate the separate effect of pretreatment 
BBB disruption and circulating biomarkers on reperfu-
sion injury. Moreover, we will investigate the combined 
effect of BBB disruption and circulating biomarkers in 
relation to reperfusion injury. Results may help to iden-
tify imaging and circulating biomarkers useful for selec-
tion of patients in future clinical trials.
MEthods
design
This is an observational prospective single-centre hospi-
tal-based study that will include 140 consecutive patients 
who had an ischaemic stroke. Circulating biomarkers 
sampling and CTP will be performed before acute inter-
ventions. Clinical, imaging and circulating biomarkers 
assessment will be repeated 24 hours after interven-
tions. Clinical evaluation will be repeated 3 months after 
the index stroke (table 1). Study protocol is registered 
at http://www. clinicaltrials. gov ( ClinicalTrials. gov ID: 
NCT03041753).
Study population
The study will include patients who had an acute isch-
aemic stroke in the anterior circulation with National 
Institutes of Health Stroke Scale (NIHSS) ≥711 within 
12 hours from last time seen well, treated with systemic 
thrombolysis, endovascular treatment or both. Post-
stroke functional status will be measured with the modi-
fied Rankin Scale (mRS) administered at 3 months by 
visit or phone interview. We will rate HT grade using the 
European Cooperative Acute Stroke Study (ECASS II) 
criteria.12 Collection of clinical data will be blinded to the 
biomarkers’ results. Key inclusion and exclusion criteria 
are summarised in table 2.
Imaging protocol
Cerebral imaging will include baseline plain CT, CT angi-
ography and CT perfusion (CTP). CT will be repeated at 
24 hours and at any time if clinical deterioration occurs. 
Collection of imaging data will be blinded to both clin-
ical and laboratory data. Baseline and follow-up CT scans 
will be assessed by three stroke physicians (FA, BP and 
VP) for presence of early ischaemic signs (Alberta Stroke 
Table 1 Schedule of assessment
Clinical data
0
(pretreatment) 24–36 hours
7 days/
discharge 3 months
Demographic variables x
Functional status (mRs) x x
Vascular risk factors x
Medications x x x x
NIHSS x x x x
Blood pressure x x x x
Neuroimaging
Plan CT x x
CT perfusion x
CT angiography x
Recanalisation assessment (CT angiography, MR 
angiography and transcranial Doppler)
x
Blood samples x x
mRs, modified Rankin scale; NIHSS, National Institutes of Health Stroke Scale.
Table 2 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Acute stroke eligible for 
systemic thrombolysis or 
endovascular treatment or 
both
Ischaemic stroke in posterior 
circulation
Age ≥18 years Contraindication for iodine 
contrast medium
NIHSS ≥7 >12 hours from last time seen 
well
NIHSS, National Institutes of Health Stroke Scale.
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Programme Early CT score and hyperdensity of middle 
cerebral artery) and presence and severity of small 
vessel disease markers. Cerebral oedema will be assessed 
according to the Safe Implementation of Thrombolysis 
in Stroke-Monitoring Study protocol.13 We will rate white 
matter changes with the Van Swieten Scale, then will 
combine the posterior (range 0–2) and anterior (range 
0–2) scores into a five-point ordinal scale (0–4).14 We 
will record the presence and number of lacunes, defined 
as round or ovoid shaped small cerebrospinal fluid 
(CSF) attenuation areas ≤2 cm in diameter in subcortical 
white and deep grey matter.15 We will define brain atrophy 
as deep or cortical and will score with a three-point ordinal 
scale as none, moderate or severe against a reference CT 
brain template,16 then will combine the single scores into 
global atrophy five-point ordinal scale. Presence and site 
of vessel occlusion will be assessed with CT angiography 
scans. Presence and grade of collaterals will be assessed 
with multiphase CT angiography sequences. Collaterals 
will be graded into good, moderate and poor, according 
to the original publication.17 We will assess presence and 
grading of HT on 24 hours CT scan according to ECASS II 
criteria12 when visible at the follow-up CT scan. CTP studies 
will be performed with a two-phase acquisition protocol, 
and permeability maps will be generated for each patient 
by Olea Sphere 3.0 (Olea Medical, La Ciotat, France) 
at baseline with a deconvolution-based delay-insensitive 
algorithm (figure 1). For permeability calculation, we will 
use Extended Tofts Model (Ktrans=mL/100 g/min).18
In case of patients with no clinical improvement, we 
will assess recanalisation at 24 hours with either CT angi-
ography, MR angiography or transcranial Doppler. In 
patients treated with endovascular procedures with effec-
tive recanalisation and clinical improvement, we will not 
reassess recanalisation at 24 hours, and we will assume the 
recanalisation to be as it was at the end of the endovas-
cular treatment.
Laboratory protocol
Blood will be collected before and 24 hours after acute 
interventions. Tubes will be centrifuged at room tempera-
ture at 1500×g for 15 min, and the supernatants will be 
stored in aliquots at −80°C. The complete list of biomarker 
under study is depicted in table 3. Novel candidates that 
will emerge over the course of the study will be consid-
ered for analysis. Thrombus obtained after endovascular 
procedure will be placed into RNA stabilisation reagent 
and stored at −80°C for global gene expression analysis.
treatment or intervention
No adjunctive selective study-related interventions are 
planned. Patients are treated following current guidelines.
Primary endpoint
 ► Relevant HT (defined as haemorrhagic infarction 
type two or any type of parenchymal haemorrhage 
(PH1 and PH2)) at 24 hours CT.
secondary endpoints
 ► Symptomatic HT (defined as any deterioration in 
NIHSS score or death combined with intracerebral 
haemorrhage of any type) at 24 hours CT.
 ► Categorical shift in mRS score 3 months after the 
index stroke.
statistical analysis
We will describe general characteristics of the study popu-
lation, and test differences using Pearson χ2 for categor-
ical variables, analysis of variance and Mann-Whitney U 
test for numeric variables, as appropriate. BBB disruption 
and differences in biomarkers levels between baseline 
and 24 hours will be evaluated according to their distribu-
tion. In case of skewed distribution of biomarker values, 
we will consider the possibility of log-transformation of 
data. Considering a possible effect of systemic thrombol-
ysis on biomarker levels, the patient cohort will be divided 
in two groups on the basis of treatment received at base-
line (systemic thrombolysis vs mechanical thrombectomy 
alone). For imaging data, as a main explanatory vari-
able, we will use BBB disruption values. For biomarkers 
data, as a main explanatory variable, we will use single 
patient’s relative prethrombolysis and post-thrombolysis 
variation (Δ median value) of biomarker levels, calcu-
lated according to the formula: (24 hours post-tissue Plas-
minogen Activator biomarker levels–pre-tPA biomarker 
levels)/pre-tPA biomarker levels.6 Differences in these Δ 
values will be analysed in relation to demographic and 
clinical features and across subgroups of patients with 
different outcomes. The net effect of each biomarker 
(baseline, 24 hours and Δ values) on outcomes will be also 
Figure 1 CT perfusion. Permeability map of middle cerebral 
artery territory on the affected side compared with the 
contralateral hemisphere.
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estimated by both logistic regression and ordinal models, 
including potentially confounding covariates, such as age, 
sex, baseline stroke severity and onset-to-treatment time.
data monitoring body
Data are currently registered in the web-based registry 
available at http://www. stroketeam. it/ risks/. Quality 
controls are done on a weekly basis. Imaging data are 
instantly checked for protocol conformity. Biosamples 
are processed using standard and harmonised operating 
procedures.
sample size
We plan to include 140 patients. The sample size was 
calculated using observational data from a pilot study 
conducted in 32 patients who had a similar stroke by our 
group.19 Permeability values above the threshold within 
the ischaemic core were found in 38% of patients who 
had a stroke. Considering a statistical power of 0.80 (alpha 
error of 0.05), we estimated a sample size of 140 patients 
to demonstrate an effect of significant BBB disruption on 
relevant HT in at least 22% of patients.
Enrolment started on October 2015 and is ongoing. 
Using a definite protocol, a prospective collection of 
data and an adequate number of patients, this study will 
integrate clinical information about biological factors 
involved in reperfusion injury after cerebral ischaemia.
Patient and public involvement
Patient and Public Involvement in the development of 
the research question, in outcome measures and in the 
design of this study could not be planned. Results will be 
disseminated through patient’s association.
dIsCussIon
Circulating and neuroimaging biomarkers of reperfusion 
injury measured in the acute ischaemic stroke setting repre-
sent potentially useful predictors of undesirable complica-
tions after recanalisation procedure. On the basis of the 
results of three small studies, CTP seems to have high sensi-
tivity and specificity to predict HT after acute ischaemic 
stroke.20–22 MRI data from 41 patients evaluated for acute 
stroke have shown an association between BBB disruption 
at 24 hours (defined as gadolinium enhancement of CSF 
on fluid-attenuated inversion recovery (FLAIR) MRI) and 
baseline levels of MMP9.9 In a larger cohort of 180 patients 
who had an acute stroke, T2 FLAIR hyperintensities, 
possible expression of vasogenic oedema in the setting of 
BBB disruption, turned out to be associated with both base-
line MMP-9 level and risk of haemorrhage.10
The RISKS combines advanced neuroimaging tech-
niques for the study of BBB disruption with analyses of 
circulating biomarkers as potential predictors of reperfu-
sion injury after acute phase interventions. The following 
considerations motivate this study: (1) in the human 
setting, the biological mechanisms of reperfusion injury 
remain incompletely described and understood; (2) a 
better knowledge of the underlying mechanisms may help 
discriminating patients at risk for complications from those 
who may definitely benefit from targeted interventions; (3) 
the validation of surrogate diagnostic markers of reperfu-
sion damage such as BBB disruption may help designing 
and conducting clinical trials testing effectiveness of reper-
fusion injury antagonists.
Results of a pilot study conducted by our group19 and 
the successful enrolment of our first 100 patients may 
Table 3 List of biomarkers
Biomarkers Methods Rationale
Metalloproteinases and inhibitors 
  Matrix  metalloproteinases (MMPs) 1, 2, 3, 
7, 8, 9, 10, 12, 13, (EMMPRIN)
Multiplex technology (R&D System, Milan, 
Italy)
Numerous studies have 
documented increases in MMPs, 
specifically MMP-9 levels following 
stroke with disruption of the blood–
brain barrier (BBB)23
  TIMP 1, 2, 3, 4 R&D assays (R&D System)
  MMP 2, 9 Activity Polyacrylamide gel (Precast Bio-rad 
Criterion 10% Zymogram Gelatin)
Endothelial dysfunction and inflammation
  von Willebrand factor (vWf), D-Dimer, PAI-1 Immunoturbidimetric method ACL TOP 
(Instrumentation Laboratory)
PAI-Ag ELISA (Technoclone)
In experimental models, systemic 
inflammation seems to alter 
the kinetics of cerebrovascular 
tight junction determining BBB 
disruption.24
  IL-1, IL-1beta; IL-4, IL-10, IL-6, IL-8, IL-12, 
IL17, IFNγ, TNF-alpha, VEGF, MIP-1 alpha/
beta, IP-10, Monocyte chemoattractant 
protein 1 (MCP-1), CRP, A2M, haptoglobin, 
P-selectin, E-selectin
Multiplex technology (BioPlex 200 System; 
BioRad, Italy)
  ICAM-1 and VCAM-1 Multiplex technology (BioPlex 200 System)
A2M, alpha2 macroglobulin; CRP, C reactive protein; EMMPRIN, Extracellular matrix metalloproteinase inducer;  ICAM-1, intercellular 
adhesion molecule 1; IFN, interferon; IL, interleukin; IP-10, IFN gamma-inducible protein 10; MIP, macrophage inflammatory protein; PAI-
1, plasminogen activator inhibitor-1; TIMP, tissue inhibitor of metalloproteinase; TNF, tumour necrosis factor; VCAM-1, vascular cell adhesion 
protein 1; VEGF, vascular endothelial growth factor.
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corroborate applicability and feasibility of our study 
protocol.
EthICs And dIssEMInAtIon
Informed consent is obtained by each patient before enrol-
ment. A full explanation of the study, a written ‘Patient Infor-
mation Sheet’ (detailing rationale, design and personal 
implications of trial entry) and informed consent form is 
provided. The consent process is deferred when the partic-
ipant lacks the capacity to provide consent. Researchers 
interested in testing hypotheses with the data are encour-
aged to contact the corresponding author. Results from 
the study will be disseminated at national and international 
conferences and in MD and PhD medical theses.
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